GYPA

Across TCGA pan-cancer cohorts, GYPA mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated GYPA data layer compared with 20 for mass-spec protein and 5 for mutation status.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher GYPA mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated GYPA expression acts as an unfavorable survival marker, although some lineages such as CCRCC and HNSC show a favorable association.

CCRCC, LUAD, and UCEC are the cancer types where GYPA mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CCRCC	DFS	Tertile	All	0.965	0.602	<.001	37	view →
LUAD	DFS	Tertile	III,IV	0.460	0.995	.013	8	view →
UCEC	DFS	Median	III,IV	0.376	0.850	.035	6	view →
HNSC	OS	Quartile	II,III,IV	0.983	0.785	.018	4	view →
LSCC	DFS	Tertile	II,III,IV	0.850	1.000	.046	1	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

GYPA–CCRCC (DFS)

Open the CCRCC breakdown →